MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
14.07
-0.18
-1.26%
Closed 19:44 12/29 EST
OPEN
14.16
PREV CLOSE
14.25
HIGH
14.21
LOW
13.80
VOLUME
2.09M
TURNOVER
0
52 WEEK HIGH
61.59
52 WEEK LOW
13.76
MARKET CAP
846.28M
P/E (TTM)
-8.4000
1D
5D
1M
3M
1Y
5Y
1D
3 ‘Strong Buy’ Stocks to Buy Today,12/29/2025, According to Top Analysts
TipRanks · 20h ago
Weekly Report: what happened at JANX last week (1222-1226)?
Weekly Report · 1d ago
Maintaining Buy on Janux: Trial Progress and Undervalued Pipeline Create Compelling Risk–Reward
TipRanks · 3d ago
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Janux Therapeutics Inc (JANX)
TipRanks · 5d ago
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence
NASDAQ · 6d ago
Janux Therapeutics Provides Phase 1 Update on EGFR-Targeted JANX008; The Program Has Initiated Expansion Cohorts To Enable Further Evaluation And Support Continued Dose Optimization Across Selected Solid Tumor Settings
Benzinga · 6d ago
Janux Therapeutics Advances Phase 1 Study of EGFR-Targeted JANX008 in Solid Tumors
Reuters · 6d ago
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.